Prescription peptide medicines
Many peptides are FDA-approved prescription drugs and are entirely legal to use as prescribed — for example semaglutide for diabetes and weight management, or leuprolide in oncology and fertility. These are obtained through a pharmacy with a valid prescription and used under medical supervision.
'Research use only' and research chemicals
Many popular peptides are sold online labeled "for research use only," which is the key phrase. These compounds are not approved for human use, and it is generally unlawful to market them for human consumption. Vendors sidestep this by selling them as laboratory reagents. The result is a legal gray area: the products exist and are sold, but they are not approved medicines, are not quality-assured, and are not legally intended to be injected by people.
Compounded peptides and the FDA
Some peptides reach people through compounding pharmacies. Compounding is legal in defined circumstances, but which bulk substances may be compounded is tightly controlled by the FDA, and this is the most fast-moving corner of peptide law. The compounded-semaglutide market that grew during drug shortages — and largely ended once those shortages resolved in 2024–2025 — is a high-profile example of how quickly it shifts.
The 2026 reclassification. In April 2026 the FDA removed a group of popular peptides — including BPC-157, TB-500, injectable GHK-Cu, MOTS-c, epitalon, Semax, KPV, and others — from the "Category 2" bulk-substances list that had effectively flagged them as not to be compounded. It's easy to misread this as "these peptides are now legal." It is not. Removal from that list does not place them on the approved 503A compounding list, and they remain outside the FDA's enforcement-discretion policy — a genuine grey zone, neither prohibited nor authorized.
A federal advisory committee (the PCAC) met in July 2026 and voted to recommend several of these peptides (including BPC-157, TB-500, MOTS-c, epitalon, Semax, and KPV) for the approved compounding list, while rejecting others. Those votes are non-binding recommendations: as of this writing the FDA has not actually added any of them, and no final rule is in place. The bottom line is unchanged — none of these is an approved medicine, and their compounding status is unresolved. Separately, the FDA has proposed permanently barring compounders from using bulk semaglutide, tirzepatide, and liraglutide. Because this area is changing month to month, current FDA guidance is always the authority.
Banned in sport (WADA)
Independent of their legal status as products, a great many peptides are prohibited in sport under the World Anti-Doping Agency (WADA) code — including growth-hormone secretagogues, GH-releasing peptides, IGF-1 analogs, and others. For competitive athletes, "legal to buy" does not mean "allowed to use."
International variation
Approval and legal status differ by country. A peptide approved in one nation may be unapproved in another, and import rules vary. Always check the rules that apply where you are.
Frequently asked questions
Are peptides legal in the United States?
It depends on the specific peptide. FDA-approved peptide medicines are legal with a prescription. Many other peptides are sold 'for research use only' and are not approved for human use — a legal gray area where marketing them for human consumption is generally not lawful.
Is it legal to buy research peptides?
Peptides sold as 'for research use only' are marketed as laboratory reagents, not approved medicines. They are not quality-assured and are not legally intended for human use. This is general information, not legal advice — check the rules in your jurisdiction.
Are peptides banned in sport?
Many are. The World Anti-Doping Agency prohibits numerous peptides — including growth-hormone secretagogues, GH-releasing peptides, and IGF-1 analogs — at all times. Being able to buy a peptide does not mean it is permitted in competition.
Is compounded semaglutide legal?
Compounding is legal in defined circumstances, but the compounded-semaglutide market that grew during the drug shortage largely ended once the shortage resolved in 2025. The FDA has since proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from bulk compounding. Current FDA guidance is the authority on what is permitted.
Did the FDA make BPC-157 and other peptides legal in 2026?
Not exactly. In April 2026 the FDA removed BPC-157, TB-500, GHK-Cu, MOTS-c, epitalon, Semax, KPV and others from a list that had flagged them as not-to-be-compounded, and an advisory committee later recommended several for the approved compounding list. But those recommendations are non-binding, the FDA has not added them, and none is an FDA-approved medicine. They sit in a regulatory grey zone — not prohibited, but not authorized either.
Further reading
Selected peer-reviewed sources on this topic, labelled by type. A citation is a reference, not an endorsement.
- Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025. Peer-reviewed study
- Kopp KO, Glotfelty EJ, Li Y, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol Res. 2022. Peer-reviewed study
- De Groot AS, Roberts BJ, Mattei A, et al. Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discov Today. 2023. Peer-reviewed study